We are live on
!
Find out more
VU
Valence8 US Portfolio holdings
AUM
$286M
1-Year Est. Return
22.37%
This Fund
S&P 500
This Quarter
Est. Return
+6.13%
1 Year Est. Return
+22.37%
3 Year Est. Return
+53.91%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$241M
AUM Growth
+$49.2M
(+26%)
Cap. Flow
+$37.5M
Cap. Flow
% of AUM
15.54%
Top 10 Holdings %
Top 10 Hldgs %
93.09%
Holding
62
New
53
Increased
3
Reduced
4
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI USA Quality Factor ETF
QUAL
|
+$6.32M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$5.41M |
| 3 |
iShares MSCI Intl Quality Factor ETF
IQLT
|
+$5.34M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
+$983K |
| 5 |
Bristol-Myers Squibb
BMY
|
+$834K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Value ETF
VTV
|
+$565K |
| 2 |
iShares MSCI United Kingdom ETF
EWU
|
+$275K |
| 3 |
State Street Utilities Select Sector SPDR ETF
XLU
|
+$271K |
| 4 |
State Street Consumer Staples Select Sector SPDR ETF
XLP
|
+$244K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 4.12% |
| 2 | Financials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Solid Biosciences
SLDB
$843M
| $110K | 0.05% |
+15,728
| New | +$128K |
|
52
PUT
Janux Therapeutics
JANX
$987M
| $104K | 0.04% |
+2,300
| New | +$100K |
|
53
VistaGen Therapeutics
VTGN
$9.36M
| $103K | 0.04% |
+34,376
| New | +$117K |
|
54
CALL
BioCryst Pharmaceuticals
BCRX
$2.34B
| $99.6K | 0.04% |
+13,100
| New | +$99.6K |
|
55
Zura Bio
ZURA
$513M
| $71K | 0.03% |
+17,495
| New | +$65.4K |
|
56
Alector
ALEC
$159M
| $68.5K | 0.03% |
+14,708
| New | +$78.9K |
|
|
CLYM
57
Climb Bio
CLYM
$731M
| $61.3K | 0.03% |
+12,045
| New | +$85.2K |
|
58
CALL
C4 Therapeutics
CCCC
$389M
| $59.9K | 0.02% |
+10,500
| New | +$63.2K |
|
|
CYPH
59
Cypherpunk Technologies Inc
CYPH
$75.2M
| $47.6K | 0.02% |
+18,511
| New | +$45.4K |
|
60
Nektar Therapeutics
NKTR
$2.23B
| $33.9K | 0.01% |
+1,740
| New | +$33.2K |
|
61
CALL
Gossamer Bio
GOSS
$77.5M
| $20.4K | 0.01% |
+20,700
| New | +$19.9K |
|
|
KZR
62
DELISTED
Kezar Life Sciences
KZR
| $16.3K | 0.01% |
+2,114
| New | +$12.8K |
|
Similar funds
A
MC
IRAG
4WM
MAG
HMP
SIIL
LCM
Valence8 US's Q3 2024 Portfolio in Review
As of Q3 2024, Valence8 US held 62 positions worth $241M, up 26% from $192M the previous quarter. Its ten largest holdings account for 93% of the portfolio.
Valence8 US deployed $37.5M of net new capital in Q3 2024, opening 53 new positions and adding to 3 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 8,969 shares worth $999K.
By sector, the portfolio is most concentrated in Healthcare at 4.1% of assets, followed by Financials.
On the sell side, the largest reduction was Vanguard Value ETF, an estimated $565K trimmed.
- Valence8 US's largest Q3 2024 buy was Jazz Pharmaceuticals: 8,969 shares worth $999K.
- Valence8 US added most to iShares MSCI USA Quality Factor ETF in Q3 2024, an estimated $6.32M increase.
- Valence8 US's biggest Q3 2024 reduction was Vanguard Value ETF, cutting an estimated $565K.
- Valence8 US's ten largest holdings make up 93% of its $241M portfolio in Q3 2024.
- Valence8 US opened 53 new positions and closed 0 in Q3 2024.
- Valence8 US's portfolio value rose 26% quarter-over-quarter to $241M.
Based on Valence8 US's 13F filing for Q3 2024, filed 12 Nov 2024.